Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 10, 2005. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares, executed under authority granted by shareholders at the Annual General Meeting on May 25, 2005.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 500,000 ordinary shares of 25 pence each.
- Purchase Price: 1,325.34 pence per share.
- Treasury Holdings Post-Transaction: 103,753,000 shares.
- Shares in Issue (excluding Treasury): 5,841,770,315 shares.
Material Changes
The material change reported is the reduction of outstanding shares through a buyback program. The company purchased 500,000 shares on August 10, 2005, increasing its treasury stock holdings. No other material changes to operations or financial position are disclosed in this specific filing.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase or subscribe for securities in any jurisdiction.
Investor Verification Checklist
- Verify the total cost of the 500,000 share repurchase based on the disclosed price of 1,325.34 pence per share.
- Confirm the updated total share count (5,841,770,315 in issue) against subsequent filings to track capital structure changes.
- Review the Annual General Meeting minutes from May 25, 2005, to understand the full scope of the share buyback authority granted.
- Note that this filing does not contain quarterly or annual financial performance data; refer to Form 20-F for comprehensive financial results.